摘要
自从硼替佐米被美国FDA批准作为第一个治疗多发性骨髓瘤的药物,各种各样的硼酸化合物已经研制成了酶抑制剂。本文对过去十年的蛋白酶体、丝氨酸蛋白酶、组蛋白去乙酰化酶和其它酶的硼酸类酶抑制剂的发展状况进行综述。
关键词: 硼酸,硼替佐米,酶抑制剂,组蛋白去乙酰化酶,蛋白酶体抑制剂,丝氨酸蛋白酶
Current Medicinal Chemistry
Title:Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress
Volume: 21 Issue: 28
Author(s): H. Fu, H. Fang, Jie Sun, H. Wang, A. Liu, J. Sun and Z. Wu
Affiliation:
关键词: 硼酸,硼替佐米,酶抑制剂,组蛋白去乙酰化酶,蛋白酶体抑制剂,丝氨酸蛋白酶
摘要: Since Bortezomib was approved by US FDA as the first drug to treat multiple myeloma, various boronic acid compounds have been developed as enzyme inhibitors. This paper reviewed the progress of boronic acid-based inhibitors against enzymes including proteasome, serine protease, HDACs and other enzymes in the past decade.
Export Options
About this article
Cite this article as:
Fu H., Fang H., Sun Jie, Wang H., Liu A., Sun J. and Wu Z., Boronic Acid-based Enzyme Inhibitors: A Review of Recent Progress, Current Medicinal Chemistry 2014; 21 (28) . https://dx.doi.org/10.2174/0929867321666140601200803
DOI https://dx.doi.org/10.2174/0929867321666140601200803 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |

- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Investigating the In Vivo Expression Patterns of miR-7 microRNA Family Members in the Adult Mouse Brain
MicroRNA Immunohistochemical and Serological 90K / Mac-2BP Detection in Hepatocellular Carcinoma Patients: Different Behaviour of Two Monoclonal Antibodies
Medicinal Chemistry Multi-Nuclear Platinum Drugs: A New Paradigm in Chemotherapy
Current Medicinal Chemistry - Anti-Cancer Agents Roles of NHERF1/EBP50 in Cancer
Current Molecular Medicine Therapeutic Vaccines Explored in Patients with Non-Small Cell Lung Cancer
Anti-Cancer Agents in Medicinal Chemistry Antisense Strategies
Current Molecular Medicine A Wnt-ow of Opportunity: Targeting the Wnt/β-Catenin Pathway in Breast Cancer
Current Drug Targets T Cell Replicative Senescence in Human Aging
Current Pharmaceutical Design Functional Link between BRCA1 and BAP1 through Histone H2A, Heterochromatin and DNA Damage Response
Current Cancer Drug Targets Clinical Significance of Mesothelin in Pancreatic Cancer
Current Signal Transduction Therapy Chimeric Antigen Receptor T Cells: Self-Replicating Drugs for Cancer
Current Drug Targets Telomere Maintenance Mechanisms in Cancer: Clinical Implications
Current Pharmaceutical Design HtrA Protease Family as Therapeutic Targets
Current Pharmaceutical Design MicroRNAs as Diagnostic, Prognostic and Predictive Biomarkers of Ovarian Cancer
Recent Patents on Biomarkers Tumor Control by Manipulation of the Human Anti-Apoptotic Survivin Gene
Current Cancer Therapy Reviews Identification of AHSA1 as a Potential Therapeutic Target for Breast Cancer: Bioinformatics Analysis and <i>in vitro</i> Studies
Current Cancer Drug Targets Anticancer Properties of the IL-12 Family - Focus on Colorectal Cancer
Current Medicinal Chemistry Immune Checkpoint Regulators: A New Era Toward Promising Cancer Therapy
Current Cancer Drug Targets Potential of DNMT and its Epigenetic Regulation for Lung Cancer Therapy
Current Genomics Meet Our Regional Editor
Anti-Cancer Agents in Medicinal Chemistry